Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance

 
• By Jung Won Shin

Kolon Life Science has reached a sizable license deal with Mundipharma for the development in Japan of the South Korean company’s first-in-class cell and gene therapy for osteoarthritis of the knee, easing uncertainties after an agreement with Mitsubishi Tanabe for the product collapsed last year.

Kolon Life and Mundipharma
Kolon Life and Mundipharma ink license agreement for Invossa • Source: Shutterstock

More from South Korea

More from Focus On Asia